GlassScriptPhysician profile
David Gerald Robertson
NPI 1659378560
$1,378,301.17
in general payments reported to CMS, 2019-2025
75 companies · $190K in 2025
The $190K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $392K · 2020: $276K · 2021: $131K · 2022: $178K · 2023: $111K · 2024: $101K · 2025: $190K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $282K · Consulting Fee: $40K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Travel and Lodging: $24K · Food and Beverage: $15K · Honoraria: $14K · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $281,816.94 |
| Consulting Fee | $39,591.81 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,881.56 |
| Travel and Lodging | $24,469.05 |
| Food and Beverage | $14,737.41 |
| Honoraria | $14,175.00 |
| Education | $165.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $566,763.59 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $340,597.74 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $241,528.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57,820.28 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Acella Pharmaceuticals, LLC | $56,428.37 | 2021-2025 | NP Thyroid 60 |
| Amgen INC. | $30,155.25 | 2019-2025 | Repatha, Tepezza, Evenity |
| Sanofi-Aventis U.S. LLC | $29,715.88 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14,350.60 | 2021-2025 | |
| Novo Nordisk As | $11,188.71 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $8,962.55 | 2019-2024 | Xifaxan, Cycloset, Trulance |
| Corcept Therapeutics | $3,117.65 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $3,039.60 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $2,650.00 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $1,550.00 | 2021 | |
| Abbott Laboratories | $1,430.92 | 2019-2025 | Freestyle Libre 3 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diabetes Care, INC. | $853.72 | 2019 | |
| Insulet Corporation | $722.11 | 2019-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $671.78 | 2022-2025 | |
| Beta Bionics, INC. | $541.74 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $486.99 | 2020-2025 | Unithroid |
| Mannkind Corporation | $440.18 | 2019-2025 | |
| Horizon Therapeutics Plc | $427.28 | 2019-2023 | Tepezza |
| Abbvie INC. | $316.70 | 2019-2024 | Synthroid |
| Radius Health, INC. | $294.47 | 2021-2025 | Tymlos |
| Bigfoot Biomedical INC | $279.22 | 2022-2023 | Unity Diabetes Management System |
| Amarin Pharma, INC. | $278.37 | 2019-2022 | |
| Ibsa Pharma INC. | $257.60 | 2019-2025 | Tirosint, Licart, Tirosint |
| Medtronic Minimed, INC. | $245.41 | 2019-2020 | |
| Madrigal Pharmaceuticals | $201.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Esperion Therapeutics, INC. | $196.49 | 2020-2024 | Nexletol |
| Becton, Dickinson and Company | $194.55 | 2019-2022 | |
| Dexcom, INC. | $176.60 | 2020-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $173.28 | 2020-2025 | Isturisa, Signifor Lar |
| Zealand Pharma US, INC. | $160.70 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $158.13 | 2019-2020 | |
| Medtronic, INC. | $141.42 | 2021-2023 | Minimed 780g |
| Cequr Corporation | $131.07 | 2021-2025 | Cequr Simplicity |
| Averitas Pharma INC. | $114.39 | 2024-2025 | Qutenza |
| Kvk-Tech, INC. | $110.21 | 2019 | |
| Neurocrine Biosciences, INC. | $103.20 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $96.72 | 2020-2024 | Contrave, Nexlizet, Nexletol |
| Merck Sharp & Dohme LLC | $96.72 | 2020-2023 | Steglatro, Steglujan, Januvia |
| Endo Pharmaceuticals INC. | $87.73 | 2019-2023 | Aveed, Xiaflex |
| Valeritas, INC. | $77.37 | 2019 | |
| Eisai INC. | $67.30 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $64.08 | 2021-2024 | Strensiq |
| Intuity Medical INC | $60.18 | 2022 | |
| Lifescan, INC. | $59.27 | 2019-2022 | |
| Astellas Pharma US INC | $59.00 | 2024-2025 | Veozah |
| Chiesi USA, INC. | $54.76 | 2024-2025 | Mycapssa, Myalept |
| Kyowa Kirin, INC. | $53.14 | 2024-2025 | Crysvita |
| Grt US Holding, INC. | $46.79 | 2021-2022 | |
| Amphastar Pharmaceuticals, INC. | $45.14 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $43.41 | 2024-2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $41.21 | 2021-2022 | |
| Embecta Corp. | $40.40 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $40.16 | 2019-2021 | |
| Nevro Corp. | $37.84 | 2021-2024 | Senza |
| Nalpropion Pharmaceuticals LLC | $32.76 | 2019 | |
| Tolmar, INC. | $31.07 | 2025 | Jatenzo |
| Amryt Pharma Holdings LTD | $29.22 | 2021-2022 | |
| Daiichi Sankyo INC. | $24.35 | 2019 | |
| Genentech USA, INC. | $21.52 | 2023 | Vabysmo |
| Soleno Therapeutics, INC. | $21.50 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $20.77 | 2025 | Twiist |
| Shire North American Group INC | $18.39 | 2019 | |
| Antares Pharma, INC. | $17.08 | 2020 | |
| Vivus LLC | $13.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.39 | 2021 | |
| Aytu Biopharma, INC. | $11.05 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$309.86 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.